Analyzing Delcath Systems (NASDAQ:DCTH) & Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ:VCYT) and Delcath Systems (NASDAQ:DCTH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Insider & Institutional Ownership

61.1% of Delcath Systems shares are held by institutional investors. 1.4% of Veracyte shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Veracyte and Delcath Systems”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15 million	5.11	$66.35 million	$0.83	39.87
Delcath Systems	$85.23 million	4.37	$2.70 million	$0.07	154.29

Veracyte has higher revenue and earnings than Delcath Systems. Veracyte is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Veracyte has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Profitability

This table compares Veracyte and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	12.83%	8.05%	7.38%
Delcath Systems	3.17%	2.63%	2.39%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Veracyte and Delcath Systems, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	3	4	0	2.38
Delcath Systems	1	0	5	0	2.67

Veracyte presently has a consensus price target of $43.83, indicating a potential upside of 32.47%. Delcath Systems has a consensus price target of $22.50, indicating a potential upside of 108.33%. Given Delcath Systems’ stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Veracyte.

Summary

Veracyte beats Delcath Systems on 8 of the 14 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.